Confounding by Indication in Real-World Indomethacin Use for Post-ERCP Pancreatitis: Implications for Severity and Cost
Digestive Diseases and Sciences · 2026
DOI: 10.1007/s10620-026-10151-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift Digestive Diseases and Sciences, 2026. Verfasst von Aziz Eshov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Skagit Regional Health, 1415 E Kincaid St, Mount Vernon, WA, 98274, USA. AzizEshov@gmail.com. Hauptthemen laut MEDLINE: Indomethacin, Cholangiopancreatography, Endoscopic Retrograde, Pancreatitis, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit nennt 20 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND AND AIMS: Rectal indomethacin is recommended for PEP prevention, but real-world effectiveness may differ due to selective use in higher-risk patients. This study evaluated the association between indomethacin use and PEP, severity, and cost implications of selective versus routine prophylaxis. METHODS: A retrospective cohort study of 332 ERCP procedures at a level III community hospital compared two endoscopists: selective versus routine administration. Firth penalized logistic regression evaluated PEP predictors. Severity was classified using Cotton and Revised Atlanta criteria. Cost analysis incorporated institutional acquisition and estimated hospitalization costs. RESULTS: Indomethacin was administered in 100 cases (30.1%). PEP occurred in 19 patients (5.7%), with no significant difference between groups. In adjusted analysis, indomethacin was not associated with PEP (odds ratio [OR] 1.26, 95% confidence interval [CI] 0.32-4.56, p = 0.74), while guidewire passage into the pancreatic duct (OR 5.25, p = 0.004) and prior PEP (OR 5.68, p = 0.001) were significant predictors. Indomethacin use was strongly associated with procedural difficulty, consistent with confounding by indication. Severe pancreatitis occurred only in the non-indomethacin group, though underpowered. Acquisition costs ranged from $262 to $532 per dose ($79-$160 per ERCP). At base-case PEP hospitalization cost of $20,000, mean total cost per ERCP was $1,263 for selective versus $1,173 for routine use; across all assumptions, costs were driven by PEP incidence rather than medication utilization. CONCLUSION: Indomethacin use was driven by procedural risk factors and not independently associated with reduced PEP. Economic outcomes were more sensitive to complication rates than drug costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, Skagit Regional Health, 1415 E Kincaid St, Mount Vernon, WA, 98274, USA. AzizEshov@gmail.com.
- Department of Gastroenterology, Skagit Regional Health, 1415 E Kincaid St, Mount Vernon, WA, 98274, USA.
- College of Osteopathic Medicine, Pacific Northwest University of Health Sciences, Yakima, WA, USA.
- The Ohio State University, Columbus, OH, USA.
Zitieren
APA
Eshov, A., Legaspi, S., Parikh, H., Dwivedy, D., Mann, G., Datta, J., Alagugurusamy, S., & Datta, S. (2026). Confounding by Indication in Real-World Indomethacin Use for Post-ERCP Pancreatitis: Implications for Severity and Cost. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-026-10151-0
Vancouver
Eshov A, Legaspi S, Parikh H, Dwivedy D, Mann G, Datta J, et al. Confounding by Indication in Real-World Indomethacin Use for Post-ERCP Pancreatitis: Implications for Severity and Cost. Digestive Diseases and Sciences. 2026. doi:10.1007/s10620-026-10151-0
BibTeX
@article{Eshov2026,
author = {Eshov, Aziz and Legaspi, Sharleen and Parikh, Harsh and Dwivedy, Devansh and Mann, Gurvansh and Datta, Jayanta and Alagugurusamy, Sankar and Datta, Samit},
title = {Confounding by Indication in Real-World Indomethacin Use for Post-ERCP Pancreatitis: Implications for Severity and Cost},
journal = {Digestive Diseases and Sciences},
year = {2026},
doi = {10.1007/s10620-026-10151-0}
}
EUVIMED